Physician profile
Xiaohui Fan
NPI 1245276252
$4,146.69
in general payments reported to CMS, 2019-2025
25 companies · $338 in 2025
The $338 reported for 2025 was less than what a typical Pain Medicine (Physical Medicine & Rehabilitation) provider received nationally (typical 2025 total: $400).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $717 · 2020: $397 · 2021: $844 · 2022: $853 · 2023: $596 · 2024: $401 · 2025: $338.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,336.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,335.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,051.74 | 2021-2025 | |
| Amgen INC. | $404.11 | 2019-2022 | |
| Pfizer INC. | $282.68 | 2019-2025 | |
| Allergan, INC. | $199.69 | 2019-2021 | |
| Novo Nordisk INC | $188.80 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Scilex Pharmaceuticals INC. | $170.32 | 2019-2020 | |
| Abbott Laboratories | $146.47 | 2020-2023 | Proclaim |
| Valinor Pharma, LLC | $115.04 | 2023-2024 | Movantik |
| Novartis Pharmaceuticals Corporation | $63.86 | 2019-2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $59.44 | 2022 | |
| Amarin Pharma, INC. | $58.08 | 2019-2022 | |
| Ipsen Biopharmaceuticals, INC | $57.57 | 2019-2020 | |
| Biohaven Pharmaceuticals, INC. | $46.81 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $44.86 | 2019 | |
| Exact Sciences Corporation | $38.29 | 2023 | Cologuard Collection Kit |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $35.09 | 2021-2024 | Mounjaro |
| Collegium Pharmaceutical, INC. | $28.69 | 2019 | |
| Depuy Synthes Sales INC. | $27.40 | 2019-2021 | |
| Averitas Pharma INC. | $26.23 | 2025 | Qutenza |
| Astrazeneca Pharmaceuticals LP | $22.94 | 2019 | |
| Pacira Pharmaceuticals Incorporated | $18.58 | 2024 | Zilretta, Iovera |
| Eisai INC. | $17.81 | 2021 | |
| Virtus Pharmaceuticals LLC | $15.05 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $13.78 | 2021 | |
| Spr Therapeutics, INC | $13.36 | 2025 | Sprint Pns System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Xiaohui Fan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.